Accordingly, therapeutics studies targeting various cytokines (NLRP3, IL-1 β and IL-6) [52,53,54] showed promising results and support the need for a better comprehension of the activation of the immune system during HF. The gene discussed is IL6; the disease is hydrops fetalis.